8-K current report · filed Sep 9, 2026

Cooper Companies (The) (COO) 8-K Current Report: September 9, 2026

Item 2.02Item 8.01Item EX-99.1Item EX-99.2COO overview

Short answer

Cooper Companies (The) (COO) filed an 8-K current report with the SEC on September 9, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Fiscal Q3 2026 results released September 9, 2026, covering the quarter ended July 31, 2026.

Cooper Companies (The) 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Fiscal Q3 2026 results released September 9, 2026, covering the quarter ended July 31, 2026
  • Detailed financial performance and management commentary contained in Exhibit 99.1
  • Earnings release excluded from Section 18 liability and filing incorporation absent specific reference

Item 8.01 · Other Events

  • Strategic review completed, signaling no immediate major portfolio or strategic transaction announcement
  • Increased share repurchase authorization, supporting capital returns and potentially reducing shares outstanding
  • Press release dated September 9, 2026; substantive authorization details appear in Exhibit 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $1.066B, up 1% organically, with CooperSurgical growth offset by flat CooperVision sales
  • Non-GAAP EPS $1.15, up 4%, while GAAP EPS $2.24 benefited from a $307.2M U.K. tax examination benefit
  • Free cash flow $273.0M, up 66%, supporting $339.1M of buybacks and approximately 4.9M shares repurchased
  • CooperVision channel inventory reduction pressures Q4, with guidance calling for organic growth of negative 2% to 0%
  • FY2026 non-GAAP EPS guidance $4.51-$4.55 and revenue guidance $4.229B-$4.252B, while strategic review actions target shareholder value

Item EX-99.2 · Exhibit EX-99.2

  • Strategic review completed, CooperSurgical retained after offers were deemed below shareholder value
  • Share repurchase authorization increased from $2 billion to $3 billion, with $445 million repurchased in fiscal 2026
  • Capital allocation shifts toward buybacks, CooperVision growth investments and CooperSurgical operational improvements
  • Two independent healthcare executives added to the Board, strengthening oversight and shareholder alignment
  • Initiatives target stronger sales execution, cost efficiency, logistics, direct shipping and accelerated contact-lens innovation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Cooper Companies (The) 8-K filings

Get the next COO 8-K as it lands

Follow COO for push alerts, or ask the research agent what this filing means.